Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of Amortization of Deferred Charges data on record, last reported at $436000.0 in Q4 2025.

  • For Q4 2025, Amortization of Deferred Charges rose 4.81% year-over-year to $436000.0; the TTM value through Dec 2025 reached $1.7 million, up 4.7%, while the annual FY2025 figure was $1.7 million, 4.7% up from the prior year.
  • Amortization of Deferred Charges reached $436000.0 in Q4 2025 per MIRM's latest filing, down from $443000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $443000.0 in Q3 2025 and bottomed at -$285000.0 in Q4 2021.
  • Average Amortization of Deferred Charges over 4 years is $301133.3, with a median of $411000.0 recorded in 2023.
  • Peak YoY movement for Amortization of Deferred Charges: tumbled 456.25% in 2021, then soared 32.57% in 2024.
  • A 4-year view of Amortization of Deferred Charges shows it stood at -$285000.0 in 2021, then surged by 240.0% to $399000.0 in 2023, then rose by 4.26% to $416000.0 in 2024, then rose by 4.81% to $436000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $436000.0 in Q4 2025, $443000.0 in Q3 2025, and $427000.0 in Q2 2025.